Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Preparing heterocyclic carbon compound having only o – n – s,...
Patent
1999-09-15
2000-12-26
Owens, Amelia
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Preparing heterocyclic carbon compound having only o, n, s,...
435 42, 435135, 435136, C12P 1706, C12P 762, C12P 3900
Patent
active
061657573
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
The present invention relates to a fermentation process for the production by microorganisms of compounds which are HMG-CoA reductase inhibitors, such as lovastatin and compactin. In particular, it relates to a process where an assimilable source of nitrogen or nitrogen and carbon is provided continuously or intermittently.
BACKGROUND OF THE INVENTION
A wide variety of relatively complex molecules, in particular drugs, can be produced by microorganisms during a fermentation process. Usually, the microorganism is fed with various assimilable sources of the elements required for the organism to produce the desired product.
The efficiency of production depends on a large number of factors, not least the nature of the carbon sources and the further conditions of fermentation. U.S. Pat. No. 4,231,938 (Merck) describes the cultivation of an Aspergillus microorganism in order to produce lovastatin.
U.S. Pat. No. 4,323,648 (Sankyo) also describes a process for the production of lovastatin this time using a microorganism of the genus Monascus.
Finally, U.S. Pat. No. 4,049,495 (also Sankyo) refers to the production of compactin using a Penicillium microorganism.
Buckland et al, Novel Microbial Products for Medicine and Agriculture, Eds. Demain et al, Chapter 19, 161-169 (1989, Society for Industrial Microbiology) describes the production of lovastatin by Aspergillus terreus. Fermentation development studies showed that for high lovastatin production, pH control and slow use of the carbon source was essential.
Although all of these documents refer to the production of various drugs by culturing different microorganisms, there are a number of problems associated with these processes. Most of them describe batch fermentation processes where the nutrients are added or mixed in with the microorganism in the culture medium at the beginning of the production process. Generally, (the fixed amount of) these nutrients are therefore gradually used up during fermentation. However, at the beginning of the process, because the nutrients are at relatively high concentrations, production of the drug is low because the microorganisms use carbon and nitrogen sources to grow, rather than to produce the drug. In such a process the rate of production of the drug is largely uncontrollable.
Overall production levels are low because in the batch processes nutrients are in effect supplied only once to the microorganism and so no variation (at least during production) can be conducted to balance growth of the biomass with production of the fermentation product.
The main objective of the invention is to provide a fermentation process that provides a greater degree of control and/or flexibility over production, so that the manufacturer can vary conditions to optimise production of the desired fermentation product. Surprisingly, it was found that feeding a nutrient not used to build up the compound of interest does increase the yield of the fermentation.
DESCRIPTION OF THE INVENTION
Therefore, according to a first aspect of the present invention, there is provided a (fermentation) process for the production of a compound of the general formula: ##STR1## wherein: each of R.sup.1 and R.sup.2 independently represent a hydrogen atom, a hydroxy, C.sub.1-10 alkyl, C.sub.1-10 alkoxy, C.sub.3-10 cycloalkyl or C.sub.6-10 aryl group or a C.sub.7-11 aralkyl group optionally containing one or more hetero atoms; --COOR.sup.1 (except that then R.sup.1 is not a hydroxy or alkoxy group), --OR.sup.1 or --COR.sup.1 or, when combined, complete a six-membered ring having one or two oxygen heteroatoms; can be optionally substituted with one or more halogen atoms, trifluoromethyl, hydroxy or C.sub.1-4 alkoxy groups; comprising an assimilable nitrogen (N) source and an assimilable carbon (C) source under fermentation conditions that allow the microorganism to produce the compound, wherein at least part of the nitrogen source is supplied to the culture continuously or intermittently. The carbon source may also be supplied to the culture c
REFERENCES:
XP002036624, Hosobuchi, et al, Biosci. Biochem. pp. 1414-1419 1983.
XP00203665, Hosobuchi, et al, Biotechnology., vol. 42, pp. 815-820.
XP002036626,Gbewanyo et al, Biotech.. vol. 37, pp. 1101-1107 1991.
XP002036627. Chem.Abstracts. vol, 123, Jul. 1995., No. 3 (1 page) p. 700.
XP002036628, Chem.Abstracts., vol, 115, Dec. 1991, p. 037, No. 25.
Lindsay Jennifer May
Ykema Adriaantje
DSM N.V.
Owens Amelia
LandOfFree
Nitrogen feed in statin fermentation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nitrogen feed in statin fermentation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nitrogen feed in statin fermentation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-993435